Abstract
Introduction
Lichen planopilaris (LPP) is the most common cause of inflammatory immune-mediated cicatricial alopecia. If not diagnosed and treated properly, it may lead to irreversible hair loss with a devastating impact on quality of life. However, treatment can be a challenge. In an area lacking these sorts of studies, we conducted a randomized controlled trial (RCT) to study the tolerability and therapeutic effects of topical clobetasol versus systemic mycophenolate mofetil (MMF).
Methods
A randomized, assessor- and analyst-blinded controlled trial was conducted in 60 patients with LPP in Razi Dermatology Hospital, Tehran, Iran, between February and December 2013. Patients were treated with clobetasol lotion 0.05 % applied at night or oral MMF 2 g/day and were followed for 6 months. The Lichen Planopilaris Activity Index (LPPAI) was the primary measure of response to treatment.
Results
Systemic MMF and topical clobetasol were equally effective in reducing the LPPAI over 6 months of treatment. Treatment tolerability was excellent in both groups and no serious irreversible adverse effects were detected. Satisfaction with treatment rose in the MMF group over time; however, it declined in the clobetasol group.
Conclusion
Given the similar efficacy profiles, topical clobetasol seems to be a more suitable and reasonable choice for treatment of LPP than MMF.
Similar content being viewed by others
References
Spencer LA, Hawryluk EB, English JC III. Lichen planopilaris: retrospective study and stepwise therapeutic approach. Arch Dermatol. 2009;145(3):333–4.
Goodman WT, Barrett TL. Lichen planopilaris. In: Bolognia JL, Jorrizo JL, Schafter JV, editors. Dermatology. Philadelphia: Elsevier Saunders; 2012. vol. 1, pp. 190–1, 194, 196, 1106–7, vol. 2, pp. 2178–9.
Racz E, Gho C, Moorman PW. Noordhoek Hegt V, Neumann HAM. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(12):1461–70.
Kang Hoon, Alzolibani Abdullateef A, Otberg Nina, Shapiro Jerry. Lichen planopilaris. Dermatol Ther. 2008;21(4):249–56.
Harries MJ, Sinclair RD, MacDonald-Hull S, Whiting DA, Griffiths CEM, Paus R. Management of primary cicatricial alopecias: options for treatment. Br J Dermatol. 2008;159:1–22.
Tursen U, Api H, Kaya T, Ikizoglu G. Treatment of lichen planopilaris with mycophenolate mofetil. Dermatol Online J. 2004;10(1):24.
Cho BK, Sah D, Chwalek J, Roseborough I, Ochoa B, Chiang C, Price VH. Efficacy and safety of mycophenolate mofetil for lichen planopilaris. J Am Acad Dermatol. 2010;62(3):393–7.
Price VH. The medical treatment of cicatricial alopecia. Semin Cutan Med Surg. 2006;25(1):56–9.
Assouly A, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28(1):3–10.
Chieregato C, Zini A, Barba A, Magnanini M, Rosina P. Lichen planopilaris: report of 30 cases and review of the literature. Int J Dermatol. 2003;42(5):342–5.
Ross EK. Primary cicatricial alopecia: clinical features and management. Dermatol Nurs. 2007;19(2)137–143. (quiz 144).
Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol. 2009;48(7):682–94.
Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211–25.
Tandon YK, Somani N, Cevasco NC, Bergfeld WF. A histologic review of 27 patients with lichen planopilaris. J Am Acad Dermatol. 2008;59(1):91–8.
Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50:25–32.
Harries MJ. The immunopathobiology of lichen planopilaris [thesis submitted for the degree of Doctor of Philosophy]. Manchester: Faculty of Medical and Human Sciences, University of Manchester; 2011.
Sperling LC, Nguyen JV. Commentary: treatment of lichen planopilaris, some progress, but a long way to go. J Am Acad Dermatol. 2010;62(3):387–93.
Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen planopilaris. J Am Acad Dermatol. 2003;49:667–71.
Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62:387–920.
Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol. 2007;57:47–53.
Del Park H, Rosso JQ. The emergence of mycophenolate mofetil in dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. J Clin Aesthet Dermatol. 2011;4(1):18–27.
Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60:183–99.
Surjushe A, Saple DG. Mycophenolate mofetil. Indian J Dermatol Venereol Leprol. 2008;74(2):180–4.
Shehzad A, Bokhari MA, Shaheen S. Mycophenolate mofetil: a new therapeutic option in dermatology. J Pak Assoc Derma. 2007;17:105–11.
Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007;20(4):229–38.
Allison AC, Engui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.
Buell C, Koo J. Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol. 2008;7:741–8.
Samrao A, Chew A-L, Price V. Frontal fibrosing alopecia: a clinical review of 36 patients. Br J Dermatol. 2010;163(6):1296–300.
Donati A, Assouly P, Matard B, Jouanique C, Reygagne P. Clinical and photographic assessment of lichen planopilaris treatment efficacy. J Am Acad Dermatol. 2011;64(3):597–8.
Acknowledgments
The authors are indebted to Dr. Alireza Firooz, Professor of Dermatology, Director of the Clinical Trial Center, Deputy Director of the Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences (TUMS), Dr. Hamed Hosseini, MD, MPH, PhDc, School of Public Health, TUMS, and Dr. Mohammadi, PhD, epidemiologist at TUMS.
Funding
The funding for this study was provided by the Vice Chancellor of Research of the Tehran University of Medical Sciences (TUMS).
Conflicts of interest
Vahide Lajevardi, Seyedeh Zahra Ghodsi, Azadeh Goodarzi, Pardis Hejazi, Arghavan Azizpour, and Sara Beygi have no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Additional information
Clinical trial registration number: IRCT2012102111195N1.
Rights and permissions
About this article
Cite this article
Lajevardi, V., Ghodsi, S.Z., Goodarzi, A. et al. Comparison of Systemic Mycophenolate Mofetil with Topical Clobetasol in Lichen Planopilaris: A Parallel-Group, Assessor- and Analyst-Blinded, Randomized Controlled Trial. Am J Clin Dermatol 16, 303–311 (2015). https://doi.org/10.1007/s40257-015-0122-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-015-0122-z